Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INVINCIBLE-4-SAKK: intratumoral INT230-6 followed by neoadjuvant chemoimmunotherapy in early triple-negative breast cancer
2024-512511-49-00Phase 2Authorised
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of INT230-6 in triple-negative breast cancer (TNBC) (2 arms), sponsored by Swiss Group for Clinical Cancer Research. Primary endpoint: Pathological complete response in breast and lymph nodes. Planned start Apr 2025; status: authorised.
02
Drugs
INT230-6
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2024-512511-49-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512511-49-00.